SCHEMBL6355280

SCHEMBL6355280

COc1ccc(OCc2ccccc2)c(CNC(=O)c2cccc(Cl)c2Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
HPGD P15428 2/20 0.55
MTNR1B P49286 2/20 0.55
MTNR1A P48039 4/20 0.54
MAPK8 P45983 2/20 0.53
MRGPRX4 Q96LA9 1/20 0.50
ALDH1A1 P00352 4/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
SGMS2 Q8NHU3 1/20 0.49
KDM4E B2RXH2 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TAS1R3 Q7RTX0 1/20 0.48
TAS1R1 Q7RTX1 1/20 0.48
PLA2G1B P04054 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6355643 0.88 HPGD (0.54) LMNAHPGDMRGPRX4ALDH1A1MAPT
SCHEMBL6356674 0.88 KMT2A (0.57) LMNAHPGDALDH1A1MAPTKMT2A
SCHEMBL6356922 0.86 LMNA (0.57) LMNAHPGDMAPK8MRGPRX4ALDH1A1
SCHEMBL6357846 0.85 SGMS2 (0.61) LMNAHPGDMAPK8MRGPRX4ALDH1A1
SCHEMBL6354502 0.82 KMT2A (0.54) LMNAHPGDALDH1A1MAPTKMT2A
SCHEMBL6355111 0.82 ALDH1A1 (0.58) LMNAHPGDMAPK8MRGPRX4ALDH1A1
SCHEMBL6354409 0.81 NPC1 (0.56) LMNAHPGDMAPK8MRGPRX4ALDH1A1
SCHEMBL6360998 0.80 KMT2A (0.60) LMNAHPGDMRGPRX4ALDH1A1MAPT
SCHEMBL6361721 0.80 PTGER1 (0.58) KMT2ASGMS2AKR1C3
SCHEMBL6354467 0.80 PTGER1 (0.55) HPGDMRGPRX4ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 LMNA 1197/4885HPGD 586/4885MTNR1B 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.